Codexis, Inc. (CDXS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

16/25

Growth 3 Margin 5 Expansion 3 Platform 3 Financial 2

latest quarter score

Earnings Reports

16
Codexis (CDXS) Q2 2026: $25M Capital Raise Boosts Ecosynthesis Scale-Up Amid Growing siRNA Demand
August 12, 2026
21
Codexis (CDXS) Q1 2026: Gross Margin Expands 16 Points as Ecosynthesis Platform Gains Traction
May 08, 2026
19
Codexis (CDXS) Q4 2025: EcoSynthesis Drives $38.9M Revenue Surge as RNA Platform Gains Traction
March 12, 2026
13
Codexis (CDXS) Q3 2025: Eco Platform Contracts Jump to 11, Accelerating Oligonucleotide Manufacturing Pivot
November 07, 2025
19
Codexis (CDXS) Q2 2025: Gross Margin Jumps 27 Points as Ecosynthesis Demand Outpaces Capacity
August 13, 2025
23
Codexis (CDXS) Q1 2025: Product Gross Margin Climbs to 55% as Ecosynthesis Platform Gains Commercial Traction
July 03, 2025
Codexis (CDXS) Q4 2024: Ecosynthesis Platform Nears Commercial Liftoff with Seven Active Partner Engagements
February 27, 2025

Browse all companies